Category: Allies & Partnerships


Safe and Sound: Balancing Safety with Innovation in American Sunscreens

By Cody R. Barnett, MRA Director of Communications | 10 October 2017 In Allies & Partnerships, Policy, Prevention

Currently, Americans have access to 16 sunscreen active ingredients approved by the Food and Drug Administration (FDA) to prevent skin cancer. The last time a new OTC (Over the Counter) sunscreen ingredient was added to the FDA sunscreen monograph was 1999. Meanwhile, Europeans have access to 29 sunscreen active ingredients. In the United States there are currently eight new sunscreen ingredients that are pending FDA review, which have been used in Europe – many for over ten years. These new, and potentially better, active ingredients could allow sunscreens to last longer and provide better full spectrum coverage that could help us reverse trends of increasing melanoma incidence in this country. Unlike in Europe where sunscreens are classified as cosmetics, in the United States the FDA is required to evaluate all active ingredients in sunscreens as OTC drugs. Meaning, that all U.S. sunscreen ingredients must be found generally recognized as safe and effective (GRASE) in the same manner as other OTC medications. The FDA says that this is critical to keeping us safe, but is it possible to balance innovation and safety?

Read More


Melanoma Survivor and Pro Baseball Hall of Famer Mike Schmidt Shares His “Game Plan” for Battling Cancer

By Your Cancer Game Plan | 19 September 2017 In Allies & Partnerships, Melanoma Stories, Treatment

Mike Schmidt, member of the Baseball Hall of Fame, is considered to be the greatest third baseman of all-time. As a professional athlete, he always felt invincible, but in 2013 a melanoma diagnosis threw him a curveball that he wasn’t prepared for.

Read More


Bristol-Myers Squibb Funds Two MRA Young Investigator Awards in Immuno-Oncology

By Kristen Mueller, Ph.D., MRA Scientific Program Director | 6 September 2017 In Allies & Partnerships, Science, Treatment

MRA is pleased to announce Bristol-Myers Squibb (BMS) has provided generous support for two Young Investigator Awards from our 2016-2017 grant cycle. The recipients of the Bristol-Myers Squibb - MRA Young Investigator Award are Dr. Erica Stone of The Wistar Institute and Dr. Manuel Valiente of Fundación Centro Nacional de Investigaciones Oncológicas Carlos III. MRA’s independent panel of academic experts selected these two immuno-oncology research programs to receive funding in 2017.

Read More


L’Oréal Paris USA-MRA Team Scientists shed light on how melanoma spreads

By Kristen Mueller, Ph.D., MRA Scientific Program Director | 29 August 2017 In Allies & Partnerships, Science, Treatment

MRA is extremely proud of the 289 investigators we have funded over the last decade and the exciting advances they have made toward ending suffering and death due to melanoma. While we can never highlight all of them at one time, we’re excited in this blog to highlight the work of the L’Oreal Paris USA sponsored MRA Team award.

Read More


Melanoma Research Alliance and the American Cancer Society Forge Research Partnership to Maximize Immunotherapy Benefit to Patients

By Pamela Goldsmith, MRA Director of Communications | 10 July 2017 In Allies & Partnerships, Science

The Melanoma Research Alliance (MRA) and the American Cancer Society (ACS) are partnering to fund much-needed research aimed at decreasing rare, but serious, side effects associated with checkpoint inhibitors in hopes of increasing further cancer immunotherapy benefit to patients.

Read More


MAC: A Valued Partner in the Fight Against Melanoma

By Michael Kaplan, MRA President & CEO | 10 July 2017 In Allies & Partnerships

What do you do after the melanoma diagnosis has settled in and you’ve done all you can to ensure the best health outcome for yourself? Or even worse, what do you do after you’ve lost a spouse or a child to melanoma? For the members of the Melanoma Action Coalition, the answer is clear. You take that fear or sorrow, and you mobilize.

Read More


LFFM Fundraising Event Again Reaches a Record Setting Year

By Pamela Goldsmith, MRA Director of Communications | 6 June 2017 In Allies & Partnerships, Events

Nearly 1,000 professionals from the leveraged finance community gathered for the sixth annual Leveraged Finance Fights Melanoma (LFFM) benefit and cocktail party raising a record $1.8 million in funds for the Melanoma Research Alliance (MRA), the largest private funder of melanoma research.

Read More


MRA and BJ’s Wholesale Club Partner to Launch May Campaign

By Pamela Goldsmith, MRA Director of Communications | 3 April 2017 In Allies & Partnerships, Prevention

In today’s dynamic research environment, working as a team is more valuable than ever. This May, in an effort to spotlight Melanoma Awareness month, BJ’s Wholesale Club, a warehouse club operating in 15 states and headquartered in Massachusetts, will launch its first awareness campaign in partnership with MRA to highlight the importance of prevention.

Read More


Finance Industry Rallies to Fight Melanoma

By Rachel Gazzerro, MRA Associate Director, Development & Information Management | 3 April 2017 In Allies & Partnerships, Events

Spotlighted in publications like Forbes, Bloomberg and The New York Times, the Leveraged Finance Fights Melanoma (LFFM) event, sponsored annually in New York City by the Melanoma Research Alliance (MRA) has become the premier gathering of professionals from the leveraged finance, private equity, and investment communities – all gathered together in response to melanoma.

Read More


Spotlight on MRA’s Ninth Annual Scientific Retreat

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 28 February 2017 In Allies & Partnerships, Events, Science

In mid-February, MRA held its premiere research event — the 9th Annual Scientific Retreat, in Washington, DC. A total of 297 individuals registered for the meeting representing a spectrum of key stakeholders in melanoma including academic investigators, pharmaceutical and biotech company representatives, melanoma advocates from various different non-profit organizations, donors and government officials.

Read More


Login

×